tiprankstipranks
Repare Therapeutics Inc (RPTX)
NASDAQ:RPTX
US Market

Repare Therapeutics (RPTX) AI Stock Analysis

Compare
427 Followers

Top Page

RP

Repare Therapeutics

(NASDAQ:RPTX)

46Neutral
Repare Therapeutics is facing significant financial challenges with ongoing losses and revenue volatility. While the balance sheet remains relatively stable, the technical analysis suggests bearish momentum. The valuation is unattractive due to negative earnings, but corporate restructuring and positive trial results could provide long-term potential. Overall, the stock presents high risk with uncertain prospects.
Positive Factors
Analyst Recommendation
Analyst's recommendation remains at Buy despite the net losses reported.
Financial Stability
RPTX provided updated guidance on their cash runway, now extended to late-2027, which shows improved financial stability.
Research and Development
RP-3467 shows potential for significant tumor volume reductions, including clearance, in combination with PARP inhibitors.
Negative Factors
Funding Risks
Failure to drive support for RP-3467/RP-1664 could heighten funding risk for the company.
Leadership Instability
The departure of Chief Medical Officer Maria Koehler suggests potential instability in the company's leadership.
Operational Efficiency
The board's formal approval of a 75% workforce reduction indicates significant organizational changes.

Repare Therapeutics (RPTX) vs. S&P 500 (SPY)

Repare Therapeutics Business Overview & Revenue Model

Company DescriptionRepare Therapeutics (RPTX) is a precision oncology company focused on developing novel therapeutics by targeting specific vulnerabilities in cancer cells. The company leverages its proprietary SNIPRx platform to design and develop innovative treatments aimed at synthetic lethality, a process that targets cancer cells by exploiting genetic interactions. Repare's pipeline includes several candidates in clinical and preclinical stages, aimed at addressing unmet needs in cancer treatment.
How the Company Makes MoneyRepare Therapeutics generates revenue primarily through strategic partnerships and collaborations with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and potential royalties based on the successful development and commercialization of therapeutic candidates. Additionally, the company may generate revenue from licensing agreements, where it licenses its proprietary technology and intellectual property to other companies in exchange for fees and royalties. As Repare's drug candidates progress through clinical trials and potentially reach commercialization, product sales will become a direct source of revenue.

Repare Therapeutics Financial Statement Overview

Summary
Repare Therapeutics is grappling with significant financial challenges, marked by ongoing losses and revenue volatility. Despite these issues, the balance sheet shows relative stability with a strong cash position and low leverage, offering some buffer to continue operations.
Income Statement
35
Negative
Repare Therapeutics has shown significant revenue volatility over the years, with revenue dropping to zero in the most recent period from $51.13 million the previous year and $131.83 million two years prior. The company has consistently incurred operating losses, and negative net income, indicating ongoing profitability challenges. The EBIT and EBITDA margins are negative, reflecting operational inefficiencies. However, the company showed a brief revenue surge in 2022, which might indicate potential for recovery.
Balance Sheet
60
Neutral
The company maintains a strong equity base relative to its liabilities, reflected in a low Debt-to-Equity ratio, which suggests stability. Despite consistent net losses, Repare's cash position remains robust, indicating prudent cash management. However, the Return on Equity is negative due to sustained net losses, which impacts overall shareholder returns negatively. The equity ratio has shown some decline but remains relatively healthy.
Cash Flow
50
Neutral
Repare Therapeutics has faced challenges with negative free cash flow, although the cash flow from investing activities has been positive, largely due to asset management. The operating cash flow remains negative, indicating that the company is not generating enough cash from core operations to cover expenses. However, the company has managed to sustain cash reserves, which provides liquidity to continue operations.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
53.48M51.13M131.83M7.60M135.00K
Gross Profit
53.48M-80.07M127.65M4.26M-1.65M
EBIT
-93.52M-116.22M-19.80M-108.66M-54.30M
EBITDA
-90.22M-114.27M-17.82M-107.19M-53.41M
Net Income Common Stockholders
-84.69M-93.80M-29.05M-106.91M-53.42M
Balance SheetCash, Cash Equivalents and Short-Term Investments
152.79M223.63M343.94M341.87M333.71M
Total Assets
176.51M253.90M364.07M368.71M357.09M
Total Debt
1.93M3.41M5.43M7.31M4.00M
Net Debt
-82.78M-107.86M-154.09M-327.11M-322.18M
Total Liabilities
25.38M41.82M84.56M80.29M70.26M
Stockholders Equity
151.13M212.08M279.52M288.42M286.83M
Cash FlowFree Cash Flow
-76.44M-129.10M-280.00K-87.49M-8.32M
Operating Cash Flow
-76.44M-127.16M322.00K-85.80M-6.08M
Investing Cash Flow
49.47M78.04M-175.78M-1.68M-9.76M
Financing Cash Flow
542.00K842.00K880.00K95.56M247.84M

Repare Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.05
Price Trends
50DMA
1.19
Negative
100DMA
1.83
Negative
200DMA
2.60
Negative
Market Momentum
MACD
-0.05
Positive
RSI
36.92
Neutral
STOCH
32.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPTX, the sentiment is Negative. The current price of 1.05 is below the 20-day moving average (MA) of 1.12, below the 50-day MA of 1.19, and below the 200-day MA of 2.60, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 36.92 is Neutral, neither overbought nor oversold. The STOCH value of 32.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RPTX.

Repare Therapeutics Risk Analysis

Repare Therapeutics disclosed 85 risk factors in its most recent earnings report. Repare Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Repare Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
$10.27B20.7123.13%18.49%176.71%
68
Neutral
$36.51B42.4117.33%78.01%
52
Neutral
$5.67B-31.26%104.04%87.80%
49
Neutral
$6.85B0.81-52.91%2.50%17.48%1.17%
46
Neutral
$44.64M-46.63%4.58%10.59%
40
Underperform
$35.01M41.08%-0.55%49.85%
26
Underperform
$12.66M9.52>-0.01%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RPTX
Repare Therapeutics
1.05
-3.65
-77.66%
EXEL
Exelixis
36.70
13.02
54.98%
KPTI
Karyopharm Therapeutics
4.16
-19.54
-82.45%
NERV
Minerva Neurosciences
1.81
-0.72
-28.46%
BPMC
Blueprint Medicines
88.72
-7.70
-7.99%
ARGX
Argenx Se
589.15
191.82
48.28%

Repare Therapeutics Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Repare Therapeutics Announces Major Reorganization in 2025
Negative
Feb 25, 2025

In January 2025, Repare Therapeutics announced a significant reorganization, including a 75% workforce reduction, to prioritize its Phase 1 clinical programs. This reorganization, approved on February 23, 2025, is expected to incur one-time costs of approximately $7.3 million for severance and $1.4 million for retention, with anticipated annual savings of $21 million. The departure of Chief Medical Officer Dr. Maria Koehler, effective March 31, 2025, is part of this restructuring, with severance benefits outlined. Retention bonuses are also being provided to key executives.

Business Operations and Strategy
Repare Therapeutics Shifts Focus to Phase 1 Programs
Positive
Jan 10, 2025

Repare Therapeutics announced a strategic shift to prioritize the advancement of its Phase 1 clinical programs, RP-1664 and RP-3467, along with exploring partnerships for other assets like Lunre+Camo. This re-alignment, coupled with cost and headcount reductions, is projected to extend the company’s cash runway to mid-2027, potentially enhancing its market position and creating value. Repare aims to achieve significant milestones in 2025, with initial clinical readouts for its prioritized programs and plans contingent on securing strategic partners for further developments.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.